Press release

Long COVID and ME/CFS: First systematic overview points to considerable funding gaps in treatment development and basic research

Hamburg, 10 November 2026

While public research funding for Long COVID and ME/CFS has increased noticeably since 2020, significant gaps remain: the majority of funds are directed toward healthcare research and observational studies, whereas the investigation of disease mechanisms and the clinical testing of treatments remain severely underfunded. These are the findings of a new systematic analysis from the ME/CFS Research Foundation. In light of the "National Decade against Post-Infectious Diseases" announced a year ago, we recommend establishing clear priorities to ensure that future funding is goal-oriented and aligned with existing research needs.

For people whose daily lives, careers and social participation are often severely restricted by these conditions, the development of effective treatments is crucial. It is true that public funding from 2020 to 2029, provided by the federal government, the Länder and the Innovation Committee of the Joint Federal Committee (GBA), amounts to a total of around 292 million euros. However, measured against the annual societal costs of both conditions – which exceed 64 billion euros – the current research funding amounts to only around 0.1 per cent – or roughly one per mille – of this annual burden. This is the case even if the 500 million euros earmarked for the ‘National Decade’ were to be paid out in full over ten years. 

Significant gaps in funding for interventional studies and medicines

The report ‘Research Funding for Long COVID and ME/CFS in Germany’ is the first comprehensive study to examine how much public money is being channelled into research into both conditions – and also what it is being used for:

  • There is a lack of interventional clinical research: Only 7 per cent of the initiatives (17 projects) specifically evaluate treatment approaches in interventional studies.
  • Drug research has been severely neglected: Only 5 per cent of the funding initiatives (14 projects) investigate drug-based interventions. Of the 209 million euros that could be allocated to specific projects, only 18.4 million euros (around 9 per cent) went towards drug research.
  • Overweight in healthcare research: 42 per cent of the total of 259 projects recorded, and around 122.5 million euros in funding, relate to healthcare research and interventions.
  • Basic research is lagging behind: Research into the mechanisms of disease accounts for only 20 per cent of the projects (51 projects) and 34.3 million euros (16 per cent of the allocable funds).

“The National Decade must be judged primarily on whether the research projects it funds lead to advances in drug-based treatment and whether they shorten the path to effective therapies. Symptom-focused care remains essential, but can only influence the course of the disease to a very limited extent. It is no substitute for the development of disease-modifying treatments that target biological causes,” says Joerg Heydecke, founder of the ME/CFS Research Foundation.

Guiding principle for the National Decade: Saving time through coordinated parallelisation 

The Federal Ministry for Research, Technology and Space (BMFTR) has announced funding of 500 million euros over ten years (2026–2036) for the ‘National Decade’. Of the 44.2 million euros that the Ministry has already budgeted for 2026 to 2028, the majority consists of ongoing funding schemes that were initiated under the previous government.

In view of the research backlog that has built up over time, the Foundation calls for maximising the time saved in the development of drug therapies and their introduction into standard clinical practice to become the guiding principle of the ‘National Decade’:

“A consistent and coordinated approach to conducting basic, translational and clinical research in parallel is required. Future funding initiatives should prioritise hypotheses regarding disease mechanisms for which evidence already exists – as recommended by the German National Academy of Sciences Leopoldina in its latest statement. These should be specifically assessed for their diagnostic and therapeutic relevance. Furthermore, the comprehensive evaluation of already authorised active substances through drug repurposing offers the opportunity to rapidly evaluate treatment approaches in clinical trials,” emphasises Dr Christina Buetfering, co-author of the report. 

Conducting targeted research into ME/CFS as a distinct clinical condition

Despite comparable case numbers – in Germany, around 757,000 people are affected by Long COVID and 657,000 by ME/CFS – there is a clear imbalance in research: 84 per cent of projects focus on Long COVID, but only 39 per cent (also) on ME/CFS. This is also reflected in the budget: €94.4 million was allocated to projects relating to ME/CFS, compared with €177.9 million for Long COVID.

The Foundation recommends a dedicated research focus on ME/CFS that explicitly includes people who developed the condition prior to the COVID-19 pandemic and following other infections and triggers. The decades-long research backlog on ME/CFS cannot be made up simply by including it in Long COVID projects. Future studies should also systematically take into account established ME/CFS diagnostic criteria and the cardinal symptom of post-exertional malaise (PEM), and differentiate cohorts according to triggers, clinical features and severity.

Lack of data transparency: 83 million euros with no link to specific projects

The analysis also reveals significant gaps in information: for 83 million euros – 29 per cent of the 292 million euros identified – it was not possible, despite intensive research, to determine how this amount was allocated across individual projects. Whilst the funding was known at programme level, specific details regarding the funded projects were lacking. Furthermore, in the case of institutionally funded organisations (such as the German Centres for Health Research (DZG) or non-university research institutions), activities relating to post-infectious diseases are, for the most part, not recorded or reported centrally, either in terms of content or budget.

The ME/CFS Research Foundation is therefore calling for a publicly accessible, centrally coordinated documentation and data platform modelled on international examples. This would provide transparency regarding what research is already being carried out and to what extent, and would create a reliable basis for specifically addressing existing research gaps within the framework of the ‘National Decade’.

About the study

The analysis takes into account 259 collaborative and individual projects announced up to September 2026, with a total budget of around 292 million euros. It covers funding measures implemented by the federal ministries (BMFTR, BMG), the federal states, the Innovation Committee at the GBA and the German Research Foundation (DFG) since 2020, with project durations extending to 2029. Data was collected through structured enquiries to the relevant ministries in all 16 federal states and to 18 research institutions, as well as through the systematic analysis of funding announcements, project databases, parliamentary documents and other public sources. The funding figures are approximate; institutionally funded research could largely not be included due to a lack of data. As individual projects were assigned to multiple diseases, research types or interventions, the percentage figures cannot be added together. 

Report: “Research funding for Long COVID and ME/CFS in Germany”, November 2026

Download: https://mecfs-research.org/en/fundingreport

Press contact

Thank you for your interest. Please feel free to contact us, sign up to our press mailing list and subscribe to our newsletter.

Further information on ME/CFS, the foundation and current media coverage can be found in the press section of our website: https://mecfs-research.org/press/ 

Donation info: https://mecfs-research.org/spenden/

Donation account: DE35 2004 0000 0628 5316 00 (Commerzbank)

ME/CFS Research Foundation is a non-profit limited liability company and fulfils the statutory requirements according to §§ 51, 59, 60 and 61 AO (German tax laws). It may issue donation receipts within the meaning of Section 10b of the German Income Tax Act.

About ME/CFS Research Foundation

The non-profit ME/CFS Research Foundation, based in Hamburg, funds and supports biomedical research into ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) and Long COVID. The aim is to develop diagnostic and therapeutic approaches to improve the current inadequate standard of care. The foundation works closely with researchers and ME/CFS patient organisations.

Due to a lack of research to date, there is still no effective treatment for these common and serious multisystemic diseases. The foundation funds research projects, connects researchers, ensures transparency regarding research progress, and provides facts and resources to raise awareness.

About ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) and long COVID:

ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) is a chronic, severe multisystemic condition characterised by a wide range of disorders, primarily affecting the nervous and immune systems. ME/CFS is predominantly post-infectious in origin, including as a consequence of COVID-19. It is the most severe form of Long COVID. People with ME/CFS experience pronounced physical and cognitive symptoms, a very low quality of life and often a high degree of disability. Between 60 and 75 per cent of all patients are unable to work, and many are confined to their homes or beds. The key symptom is severe worsening of symptoms following everyday activities (post-exertional malaise, or PEM for short). Due to the current lack of biomarkers, diagnosing ME/CFS is only possible through a detailed medical history and multidisciplinary diagnostic process to rule out other conditions. Many doctors lack the necessary expertise. It often takes years for those affected to receive a diagnosis. To date, there is no effective treatment. Adults with ME/CFS currently have little prospect of recovery and reintegration into working life. The prognosis is better for children and young people, yet long-term absences from school are the norm. For most sufferers, participation in normal life—including work, education, friends, sport, hobbies, etc.—is not possible.

In Deutschland lag die Zahl der Menschen, die mit ME/CFS leben, im Jahr 2025 bei mehr als 657.000. Ein Teil der durch COVID-19 an Long COVID bzw. Post-COVID-Syndrom erkrankten Personen erfüllt die Diagnosekriterien für ME/CFS. Bereits vor der COVID-19-Pandemie lebten etwa 400.000 Menschen in Deutschland mit ME/CFS. Weltweit liegt die Zahl der Betroffenen bei weit über 40 Millionen. Die medizinische Versorgungslage der Erkrankten ist ungenügend. Oft kommt es zu Fehldiagnosen und daraus resultierenden Folgeschäden.

Die hohe Zahl der Betroffenen ist für alle Bereiche der Versorgung sowie auch ökonomisch, durch den krankheitsbedingten Ausfall von Ausbildungszeit und Arbeitskraft, ein zunehmend kritischer Faktor.

All the figures and sources mentioned can be found on our website: https://mecfs-research.org/was-ist-me-cfs

Privacy overview

This website uses cookies so that we can provide you with the best possible user experience. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helps our team understand which sections of the website are most interesting and useful to you.